Aminopentamide Sulfate

Aminopentamide Sulfate

SCHEMBL251458

CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 6/20 0.75
GRIN2A Q12879 6/20 0.75
GRIN2D O15399 5/20 0.75
GRIN2C Q14957 5/20 0.75
GRIN2B Q13224 4/20 0.75
OPRM1 P35372 4/20 0.75
KCNH2 Q12809 4/20 0.75
DRD3 P35462 3/20 0.75
OPRK1 P41145 2/20 0.75
DRD4 P21917 2/20 0.75
CACNA1F O60840 1/20 0.75
ABCB1 P08183 1/20 0.75
CYP2B6 P20813 1/20 0.75
OPRD1 P41143 1/20 0.75
CACNA1D Q01668 1/20 0.75
CACNA1S Q13698 1/20 0.75
CACNA1C Q13936 1/20 0.75
MRGPRX2 Q96LB1 1/20 0.75
CHRM3 P20309 2/20 0.52
LMNA P02545 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aminopentamide Sulfate SCHEMBL203612 0.94 GRIN1 (0.68) GRIN1GRIN2AGRIN2DGRIN2CGRIN2B
SCHEMBL6264501 0.87 GRIN1 (0.74) GRIN1GRIN2AGRIN2DGRIN2CGRIN2B
SCHEMBL11422970 0.87 GRIN1 (0.74) GRIN1GRIN2AGRIN2DGRIN2CGRIN2B
SCHEMBL22313203 0.87 GRIN1 (0.74) GRIN1GRIN2AGRIN2DGRIN2CGRIN2B
Levomethadone SCHEMBL8506268 0.86 GRIN1 (1.00) GRIN1GRIN2AGRIN2DGRIN2CGRIN2B
Methadone SCHEMBL34140 0.86 GRIN1 (1.00) GRIN1GRIN2AGRIN2DGRIN2CGRIN2B
Esmethadone SCHEMBL24294 0.86 GRIN1 (1.00) GRIN1GRIN2AGRIN2DGRIN2CGRIN2B
Methadone SCHEMBL17008675 0.86 GRIN1 (1.00) GRIN1GRIN2AGRIN2DGRIN2CGRIN2B
Levomethadone SCHEMBL147864 0.86 GRIN1 (1.00) GRIN1GRIN2AGRIN2DGRIN2CGRIN2B
SCHEMBL11804700 0.86 GRIN1 (0.68) GRIN1GRIN2AGRIN2DGRIN2CGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3523325-B1 INDUCIBLE CASPASES AND METHODS FOR USE POSEIDA THERAPEUTICS INC (US) 2025-08-06 EP claimed
EP-3801523-B1 SPLICING MODULATORS EISAI R&D MAN CO LTD (JP) 2024-09-11 EP claimed
CN-116887804-A Cleaning composition 莱雅公司 2023-10-13 CN claimed
WO-2023126971-A1 ORAL FILMS OF ANTI-EMETIC DRUGS LAURUS LABS LIMITED (IN) 2023-07-06 WO claimed
CN-111179416-B Vascular vector diagram model generation method and device 北京东方逸腾数码医疗设备技术有限公司 2023-04-25 CN claimed
WO-2016073991-A2 EDIBLE CAT TOY Urban Pet Haus, LLC (US) 2016-05-12 WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1273301-B1 Pharmaceutical preparations based on active ingredients susceptible to illicit administration ALTERGON SA (CH) 2006-09-06 EP claimed
EP-1273301-A2 Pharmaceutical preparations based on active ingredients susceptible to illicit administration ALTERGON S.A. (CH) 2003-01-08 EP claimed
US-20260124217-A1 COMPOSITIONS OF BIFUNCTIONAL INHIBITORS OF TETRACYCLINE INACTIVATING ENZYMES AND METHODS OF USE THEREOF WASHINGTON UNIVERSITY (US) 2026-05-07 US disclosed
US-20260097102-A1 Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors REGENERON PHARMA (US) 2026-04-09 US disclosed
US-12472241-B2 Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors REGENERON PHARMACEUTICALS, INC. (US) 2025-11-18 US disclosed
EP-0764169-A2 DRUG SALTS DUMEX-ALPHARMA A/S (DK) 1997-03-26 EP disclosed
WO-1995034571-A2 DRUG SALTS DUMEX ALPHARMA A/S (DK) 1995-12-21 WO disclosed
US-3896221-A Anesthetic composition AMERICAN HOME PRODUCTS CORPORATION, A CORP. OF DE. 1975-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124217-A1 COMPOSITIONS OF BIFUNCTIONAL INHIBITORS OF TETRACYCLINE INACTIVATING ENZYMES AND METHODS OF USE THEREOF TDO2, TKT, COASY GRIN1 4687/4885GRIN2A 4686/4885GRIN2D 4277/4885
US-20260097102-A1 Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors ALOX15, ALOX15B, ALOX5 GRIN1 4190/4885GRIN2A 4169/4885GRIN2D 4198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.